Corvus Pharmaceuticals (CRVS) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Corvus Pharmaceuticals (CRVS) over the past year, gaining 278.1% versus a gain of 51.5%. Corvus Pharmaceuticals is the larger company by market cap ($858.9 million vs $770.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | IMMX |
|---|---|---|
| Share price | $10.21 | $9.29 |
| Market cap | $858.87M | $770.17M |
| 1-day change | -1.92% | -2.11% |
| YTD return | +35.19% | +81.45% |
| 1-year return | +51.53% | +278.09% |
| 5-year return | +110.30% | — |
| EPS (TTM) | $-0.62 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.95 | $15.10 |
| 52-week low | $6.39 | $2.31 |
| Distance from 52-week high | -62.12% | -38.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +224.58% | +161.57% |
| Average volume | 973.33K | 1.65M |
| Shares outstanding | 84.12M | 82.90M |
| Employees | 37 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed CRVS by 226.6 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CRVS vs IMMX FAQ
Which is bigger, Corvus Pharmaceuticals or Immix Biopharma?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $858.87M compared with $770.17M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, CRVS or IMMX?
IMMX returned +278.09% over the past 12 months, compared with +51.53% for CRVS (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.